Related Experiment Video
Updated: Jul 26, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
Chemoradiotherapy for Head and Neck Cancer
Ida D'Onofrio1,2, Valerio Nardone1, Alfonso Reginelli1
1Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy.
Cancers
|June 22, 2023
Summary
Head and neck squamous cell carcinoma (HNSCC) presents significant challenges in treatment. This research explores novel therapeutic strategies to improve outcomes for HNSCC patients.
Area of Science:
- Oncology
- Cancer Research
- Head and Neck Cancer
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a complex malignancy with diverse etiologies.
- Current treatment modalities for HNSCC often lead to significant morbidity.
- There is a critical need for more effective and targeted therapies for HNSCC.
Discussion:
- Investigating the tumor microenvironment in HNSCC is crucial for understanding treatment resistance.
- Exploring novel therapeutic targets, such as specific signaling pathways, holds promise for HNSCC.
- The role of immunotherapy in advanced HNSCC requires further elucidation.
Key Insights:
- Identifying predictive biomarkers for HNSCC treatment response is essential.
- Understanding the molecular heterogeneity of HNSCC can guide personalized treatment approaches.
- Early detection and risk stratification are key to improving HNSCC patient survival.
Outlook:
- Future research should focus on developing combination therapies for HNSCC.
- Clinical trials are needed to validate novel therapeutic strategies for HNSCC.
- Advancements in precision medicine offer new hope for managing HNSCC.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
251
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
251
02:49Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
353
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
353
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
208
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
208
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
326
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
326
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K